Generic Name and Formulations:
Pentavalent, live rotavirus vaccine; oral susp; contains fetal bovine serum (trace); preservative-free.
Merck & Co., Inc.
Indications for ROTATEQ:
Rotavirus gastroenteritis vaccination in infants 6–32 weeks of age.
<6 weeks or >32 weeks: not established. Each dose is 1 tube. Give 1st dose orally at 6–12 weeks of age; give 2nd and 3rd dose at 4–10 week intervals for a total of 3 doses. If incomplete dose is given, do not give replacement dose; continue with remaining doses in the recommended series.
Severe combined immunodeficiency disease. History of intussusception.
Immunocompromised (blood dyscrasias, leukemia, lymphomas, or other malignancies; primary and acquired immunodeficiency states, HIV/AIDS; cellular immune deficiencies; and hypogammaglobulinemic and dysgammaglobulinemic states; received blood transfusion or blood products, including immunoglobulins within 42 days). Febrile illness. Active or history of GI disorders. Chronic diarrhea. Failure to thrive. History of congenital abdominal disorders. Abdominal surgery. Risk of intussusception. Immunodeficient close contacts. Pregnancy (Cat. C), women of child-bearing potential: not recommended.
Immunosuppressants (eg, irradiation, chemotherapy, high-dose steroids): may get suboptimal response. Concomitant vaccines: see full labeling; oral polio vaccine: not recommended.
Diarrhea, vomiting, irritability, otitis media, nasopharyngitis, bronchospasm; rare: intussusception, hematochezia, seizures, Kawasaki disease.
Single-use tube (2mL)—10, 25
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Antibiotic Use in Neonatal Settings in Need of Improvement
- Whole Genome Sequencing Use in Predicting TB Resistance
- Rapid Antimicrobial Susceptibility Testing on Urine Directly Accelerates Results
- Antibiotics May Be Beneficial in Children With Prolonged Wet Cough
- Emergency Department Overcrowding Associated With Delayed Antibiotics in Patients With Sepsis
- Success With DAA for Hepatitis C Prior to Stem Cell Transplant
- Shorter Antibiotic Course Noninferior for Gram-Negative Bacteremia
- Dolutegravir Plus Lamivudine Promising for HIV Maintenance Therapy
- Trial Results Affected by Heterogeneous CAP Inclusion Criteria
- Screening Blood Donations Mitigates Transfusion-Transmitted Babesiosis Risk